Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pre-exposure Prophylaxis for Prevention of HIV Infection Clear all
Completed No phase listed Observational

Implantable Long-Acting Pre-Exposure Prophylaxis For MSM

NCT05420207
View directory record Official record
Conditions
HIV Prevention
Interventions
No intervention
Other
Lead sponsor
Elizabeth Arnold
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

NCT06045507
View directory record Official record
Conditions
HIV, HIV Pre-exposure Prophylaxis
Interventions
MK-8527, Placebo to MK-8527
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
10
States / cities
North Hollywood, California • San Francisco, California • Hallandale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males

NCT04692077
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir (CAB) tablet, CAB LA, Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 17 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 2, 2026, 8:05 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Naltrexone for Overdose Prevention

NCT06633900
View directory record Official record
Conditions
Overdose Accidental
Interventions
IM naltrexone, Usual Care
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

NCT02720094
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 2, 2026, 8:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP)

NCT06030557
View directory record Official record
Conditions
Hiv Prevention, Pre-Exposure Prophylaxis (PrEP)
Interventions
Truvada
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lake Worth, Florida • Miami Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 2, 2026, 8:05 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy

NCT07658976
View directory record Official record
Conditions
HIV Infection, Sexually Transmitted Infection
Interventions
HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package, Handout about HIV PrEP options available at the site, Standard-of-care HIV PrEP counseling from qualified study staff
Drug · Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years to 29 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Los Angeles, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

NCT05514509
View directory record Official record
Conditions
HIV Infections
Interventions
APRETUDE, Cabotegravir tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 2, 2026, 8:05 AM EDT
Not listed Not applicable Interventional

Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)

NCT03693040
View directory record Official record
Conditions
HIV Prevention
Interventions
Digital Health Feedback System
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 2, 2026, 8:05 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender Women

NCT07146139
View directory record Official record
Conditions
HIV Pre-exposure Prophylaxis, HIV Prevention and Care, Mobile Health Technology (mHealth), Adherence, Doxycycline STI PEP
Interventions
MyPrEP Plus Package, Standard of Care (SOC)
Device · Behavioral
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 2, 2026, 8:05 AM EDT
Recruiting Not applicable Interventional

Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women with Trauma-related Conditions

NCT06558825
View directory record Official record
Conditions
Substance Use
Interventions
Integrated Intervention to Promote PrEP Uptake, Standard Treatment Condition
Behavioral · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women

NCT01505114
View directory record Official record
Conditions
HIV Infection
Interventions
Maraviroc, Emtricitabine, Tenofovir disoproxil fumarate, Maraviroc placebo, Emtricitabine placebo, Tenofovir disoproxil fumarate placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals

NCT03086200
View directory record Official record
Conditions
Patient Adherence, HIV Seronegativity
Interventions
brief Motivational Interviewing
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 2, 2026, 8:05 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Evaluating The Acceptability and Uptake of Pre-Exposure Prophylaxis (PrEP) for Adolescent Women in The Deep South

NCT03897725
View directory record Official record
Conditions
Adolescent Behavior, HIV/AIDS, PrEP
Interventions
Telehealth Coaching
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years to 21 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Phase 3 Interventional

Next Generation Ingestible Sensors for Medication Adherence Measurement

NCT05592613
View directory record Official record
Conditions
HIV Infection, Adherence, Medication, Adherence, Treatment, Pre-Exposure Prophylaxis, Antiretroviral Therapy
Interventions
Next-generation Reader and ID-Cap System, Truvada for pre-exposure prophylaxis (PrEP), Biktarvy for antiretroviral therapy (ART)
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 2, 2026, 8:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinician Attitudes and Behaviors Regarding Use of Pre-Exposure Prophylaxis (PrEP) for Primary HIV Prevention

NCT01751659
View directory record Official record
Conditions
Clinician Attitudes About PrEP
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 2, 2026, 8:05 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Transmasculine One-on-One and Group Empowerment for Targeted HIV Reduction

NCT06182280
View directory record Official record
Conditions
HIV Infections, Adherence, Medication
Interventions
PrEP4T, LS4TM
Behavioral
Lead sponsor
Fenway Community Health
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 2, 2026, 8:05 AM EDT
Recruiting Not applicable Interventional

Pre-exposure Prophylaxis (PrEP) for Health

NCT04430257
View directory record Official record
Conditions
Substance Dependence, HIV (Human Immunodeficiency Virus)
Interventions
HIV and PrEP education, Motivational interviewing, Problem-solving and planning, Patient navigation, PrEP information, Referrals
Other · Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Cambridge, Massachusetts • Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 2, 2026, 8:05 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting

NCT07210125
View directory record Official record
Conditions
HIV
Interventions
Lenacapavir long-acting, Standard of Care (SOC)
Drug · Other
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing a Patient Navigation Intervention for PrEP Continuum of Care Among Young Latino MSM (PrEParate)

NCT04048382
View directory record Official record
Conditions
HIV/AIDS
Interventions
Patient Navigation, Usual Care
Behavioral · Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 29 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

NCT05374525
View directory record Official record
Conditions
HIV Infections
Interventions
APRETUDE, Cabotegravir OLI
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Male only
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Life Steps for PrEP for Youth

NCT03805451
View directory record Official record
Conditions
HIV, Pre-exposure Prophylaxis, Medication Adherence
Interventions
Life Steps for PrEP for Youth
Behavioral
Lead sponsor
Fenway Community Health
Other
Eligibility
16 Years to 24 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 2, 2026, 8:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peer Outreach and Navigation Intervention to Increase PrEP Uptake Among Women at High Risk for HIV

NCT03226873
View directory record Official record
Conditions
Pre-exposure Prophylaxis, HIV-1-infection
Interventions
Peer Navigation
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 2, 2026, 8:05 AM EDT